Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation

C. Voena; M. Malnati; I. Majolino; G. Fagà; V. Montefusco; L. Farina; A. Santoro; M. Ladetto; M. Boccadoro; P. Corradini

doi:10.1038/sj.bmt.1704207

Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation

C. Voena, M. Malnati, I. Majolino, G. Fagà, V. Montefusco, L. Farina, A. Santoro, M. Ladetto, M. Boccadoro, P. Corradini

Research output: Contribution to journal › Article › peer-review

Abstract

Allogeneic stem cell transplantation (allo-SCT) is an effective and potentially curative treatment for some cases of multiple myeloma (MM). The curative efficacy of allo-SCT may be largely attributed to its immunological activity, the graft-versus-myeloma (GVM) effect. To evaluate the kinetics of residual myeloma cells, we analyzed the follow-up bone marrow samples of three MM patients by means of a real-time molecular assay. We identified a consistent correlation between onset of graft-versus-host disease and disease response. These data suggest that real-time molecular follow-up can be used to monitor the GVM effect and that it can be employed in the clinical setting to tailor post transplant immunomodulation.

Original language	English
Pages (from-to)	791-793
Number of pages	3
Journal	Bone Marrow Transplantation
Volume	32
Issue number	8
DOIs	https://doi.org/10.1038/sj.bmt.1704207
Publication status	Published - Oct 2003

Keywords

Allogeneic transplantation
Graft-versus-myeloma
Multiple myeloma
Real-time PCR

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1038/sj.bmt.1704207

Fingerprint Dive into the research topics of 'Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation'. Together they form a unique fingerprint.

Cite this

Voena, C., Malnati, M., Majolino, I., Fagà, G., Montefusco, V., Farina, L., Santoro, A., Ladetto, M., Boccadoro, M., & Corradini, P. (2003). Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation. Bone Marrow Transplantation, 32(8), 791-793. https://doi.org/10.1038/sj.bmt.1704207

Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation. / Voena, C.; Malnati, M.; Majolino, I.; Fagà, G.; Montefusco, V.; Farina, L.; Santoro, A.; Ladetto, M.; Boccadoro, M.; Corradini, P.

In: Bone Marrow Transplantation, Vol. 32, No. 8, 10.2003, p. 791-793.

Research output: Contribution to journal › Article › peer-review

Voena, C, Malnati, M, Majolino, I, Fagà, G, Montefusco, V, Farina, L, Santoro, A, Ladetto, M, Boccadoro, M & Corradini, P 2003, 'Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation', Bone Marrow Transplantation, vol. 32, no. 8, pp. 791-793. https://doi.org/10.1038/sj.bmt.1704207

Voena, C. ; Malnati, M. ; Majolino, I. ; Fagà, G. ; Montefusco, V. ; Farina, L. ; Santoro, A. ; Ladetto, M. ; Boccadoro, M. ; Corradini, P. / Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation. In: Bone Marrow Transplantation. 2003 ; Vol. 32, No. 8. pp. 791-793.

@article{cfae6f3008264ea6ab834a25a6e853ca,

title = "Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation",

abstract = "Allogeneic stem cell transplantation (allo-SCT) is an effective and potentially curative treatment for some cases of multiple myeloma (MM). The curative efficacy of allo-SCT may be largely attributed to its immunological activity, the graft-versus-myeloma (GVM) effect. To evaluate the kinetics of residual myeloma cells, we analyzed the follow-up bone marrow samples of three MM patients by means of a real-time molecular assay. We identified a consistent correlation between onset of graft-versus-host disease and disease response. These data suggest that real-time molecular follow-up can be used to monitor the GVM effect and that it can be employed in the clinical setting to tailor post transplant immunomodulation.",

keywords = "Allogeneic transplantation, Graft-versus-myeloma, Multiple myeloma, Real-time PCR",

author = "C. Voena and M. Malnati and I. Majolino and G. Fag{\`a} and V. Montefusco and L. Farina and A. Santoro and M. Ladetto and M. Boccadoro and P. Corradini",

year = "2003",

month = oct,

doi = "10.1038/sj.bmt.1704207",

language = "English",

volume = "32",

pages = "791--793",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "8",

}

TY - JOUR

T1 - Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation

AU - Voena, C.

AU - Malnati, M.

AU - Majolino, I.

AU - Fagà, G.

AU - Montefusco, V.

AU - Farina, L.

AU - Santoro, A.

AU - Ladetto, M.

AU - Boccadoro, M.

AU - Corradini, P.

PY - 2003/10

Y1 - 2003/10

N2 - Allogeneic stem cell transplantation (allo-SCT) is an effective and potentially curative treatment for some cases of multiple myeloma (MM). The curative efficacy of allo-SCT may be largely attributed to its immunological activity, the graft-versus-myeloma (GVM) effect. To evaluate the kinetics of residual myeloma cells, we analyzed the follow-up bone marrow samples of three MM patients by means of a real-time molecular assay. We identified a consistent correlation between onset of graft-versus-host disease and disease response. These data suggest that real-time molecular follow-up can be used to monitor the GVM effect and that it can be employed in the clinical setting to tailor post transplant immunomodulation.

AB - Allogeneic stem cell transplantation (allo-SCT) is an effective and potentially curative treatment for some cases of multiple myeloma (MM). The curative efficacy of allo-SCT may be largely attributed to its immunological activity, the graft-versus-myeloma (GVM) effect. To evaluate the kinetics of residual myeloma cells, we analyzed the follow-up bone marrow samples of three MM patients by means of a real-time molecular assay. We identified a consistent correlation between onset of graft-versus-host disease and disease response. These data suggest that real-time molecular follow-up can be used to monitor the GVM effect and that it can be employed in the clinical setting to tailor post transplant immunomodulation.

KW - Allogeneic transplantation

KW - Graft-versus-myeloma

KW - Multiple myeloma

KW - Real-time PCR

UR - http://www.scopus.com/inward/record.url?scp=11144355241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144355241&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704207

DO - 10.1038/sj.bmt.1704207

M3 - Article

C2 - 14520423

AN - SCOPUS:11144355241

VL - 32

SP - 791

EP - 793

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 8

ER -

Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this